Literature DB >> 22050599

Availability of insulin pump therapy in clinical practice.

B-M Carlsson1, P Nord Andersson, J Alnervik, J Carstensen, M Lind.   

Abstract

AIM: To examine the availability of insulin pump therapy in patients with Type 1 diabetes.
METHODS: Patients using insulin pumps among a cohort of 7224 patients with Type 1 diabetes were studied.
RESULTS: In logistic regression, used to evaluate variables not changing over time among the total cohort, use of insulin pumps varied by outpatient clinic (P<0.001) and sex (P<0.001). Cox regression analysis in 5854 patients with detailed patient data prior to use of an insulin pump showed higher HbA(1c) (P<0.0001), lower creatinine (P=0.002), high and low insulin doses (P<0.0001), younger age (P<0.0001) and female sex (P<0.0001) to be associated with use of an insulin pump. Women were 1.5-fold more likely to start using an insulin pump (hazard ratio 1.52, 95% confidence interval 1.29-1.79) and patients in the 20- to 30-years age range were more than twice as likely to begin use of an insulin pump than patients aged 40-50 years (hazard ratio 8.63, 95% confidence interval 5.91-12.59 and hazard ratio 3.98, 95% confidence interval 2.80-5.64, respectively). A 10-μmol/l higher level of creatinine was associated with a hazard ratio of 0.56 (95% confidence interval 0.39-0.81) of starting use of an insulin pump.
CONCLUSIONS: At 10 hospital outpatient clinics in Sweden, use of insulin pumps therapy varied by clinic. A higher proportion of women began using insulin pumps. Younger patients and patients with fewer complications were also more likely to start using an insulin pump. Further research is needed to confirm these findings in other geographical regions and to understand whether the availability of insulin pumps today is optimized.
© 2011 The Author. Diabetic Medicine © 2011 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22050599     DOI: 10.1111/j.1464-5491.2011.03517.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  6 in total

1.  Availability of and access to continuous subcutaneous insulin infusion therapy for adults with type 1 diabetes in Ireland.

Authors:  Katarzyna Anna Gajewska; Regien Biesma; Kathleen Bennett; Seamus Sreenan
Journal:  Acta Diabetol       Date:  2020-03-02       Impact factor: 4.280

2.  Real-World Application of Insulin Pump Therapy Among Patients With Type 1 Diabetes in China: A Cross-Sectional Study.

Authors:  Lili Huo; Wei Deng; Ling Lan; Wei Li; Jonathan E Shaw; Dianna J Magliano; Linong Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-10       Impact factor: 6.055

3.  Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes.

Authors:  Melissa M Kallas-Koeman; Jason M Kong; Jennifer A Klinke; Sonia Butalia; Abhay K Lodha; Ken I Lim; Qiuli M Duan; Lois E Donovan
Journal:  Diabetologia       Date:  2014-01-17       Impact factor: 10.122

4.  Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden.

Authors:  Johan Jendle; Jayne Smith-Palmer; Alexis Delbaere; Simona de Portu; Natalie Papo; William Valentine; Stéphane Roze
Journal:  Diabetes Ther       Date:  2017-09-04       Impact factor: 2.945

5.  Low uptake of continuous subcutaneous insulin infusion therapy in people with type 1 diabetes in Ireland: a retrospective cross-sectional study.

Authors:  Katarzyna Anna Gajewska; Kathleen Bennett; Regien Biesma; Seamus Sreenan
Journal:  BMC Endocr Disord       Date:  2020-06-23       Impact factor: 2.763

6.  Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies.

Authors:  Karl Kristensen; Linda E Ögge; Verena Sengpiel; Karin Kjölhede; Annika Dotevall; Anders Elfvin; Filip K Knop; Nana Wiberg; Anastasia Katsarou; Nael Shaat; Lars Kristensen; Kerstin Berntorp
Journal:  Diabetologia       Date:  2019-03-23       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.